Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market
BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study
He has successfully led the development of 15 approved drugs worldwide across various therapeutic areas over his more than 20-year career
Jobevne is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
Sun Pharma is granted rights for marketing Sovateltide in India under the brand name Tyvalzi (Sovateltide)
The agreement is for the development and commercialisation of JHU’s novel target and technology that will help patients with colorectal cancer
Sandoz is committed to building on its leading generic and biosimilar oncology portfolio to further expand patient access while contributing to the sustainability of healthcare systems
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
Subscribe To Our Newsletter & Stay Updated
